Why Novo Nordisk Shares Are Trading Higher Today

The FDA has approved Novo Nordisk A/S's NVO 2.0 mg dose of Ozempic (once-weekly semaglutide subcutaneous injection), a glucagon-like peptide-1 (GLP-1) analog for type 2 diabetes.
Ozempic is now approved in the US at 0.5 mg,1.0 mg, and 2.0 mg doses to treat type 2 diabetes in adults. Further, Ozempic is indicated to reduce the risk of major cardiovascular events.
The FDA approval is based on the results from the SUSTAIN FORTE trial.
Related: Novo Nordisk Doubles 2025 Sales Target On Strong Wegovy Demand.
In the trial, people treated with semaglutide 2.0 mg achieved a statistically significant and superior reduction in HbA1c at week 40 compared to semaglutide 1.0 mg. Both doses of semaglutide appeared to have a safe and well-tolerated profile in the trial.
The most common adverse events were gastrointestinal. Compared to semaglutide 1.0 mg, the gastrointestinal adverse events were similar for semaglutide 2.0 mg.
Novo Nordisk expects to launch Ozempic 2.0 mg in the United States in Q2 of 2022.
Price Action: NVO shares are up 3.20% at $111.36 during the market session on the last check Tuesday.

Momentum9.56

Growth80.00

Quality93.21

Value7.51

Short

Medium

Long